These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23385150)

  • 1. A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium.
    Jhingran A; Ramondetta LM; Bodurka DC; Slomovitz BM; Brown J; Levy LB; Garcia ME; Eifel PJ; Lu KH; Burke TW
    Gynecol Oncol; 2013 May; 129(2):304-9. PubMed ID: 23385150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer.
    Kiess AP; Damast S; Makker V; Kollmeier MA; Gardner GJ; Aghajanian C; Abu-Rustum NR; Barakat RR; Alektiar KM
    Gynecol Oncol; 2012 Nov; 127(2):321-5. PubMed ID: 22850412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy.
    Turner BC; Knisely JP; Kacinski BM; Haffty BG; Gumbs AA; Roberts KB; Frank AH; Peschel RE; Rutherford TJ; Edraki B; Kohorn EI; Chambers SK; Schwartz PE; Wilson LD
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):77-84. PubMed ID: 9422561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Assessment of Prognostic Factors, Adjuvant Treatment, and Outcomes of Stage IA Polyp-Limited Versus Endometrium-Limited Type II Endometrial Carcinoma.
    Liang LW; Perez AR; Cangemi NA; Zhou Q; Iasonos A; Abu-Rustum N; Alektiar KM; Makker V
    Int J Gynecol Cancer; 2016 Mar; 26(3):497-504. PubMed ID: 26825840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent cisplatin/radiation followed by adjuvant cisplatin/paclitaxel in treatment of patients with stage IB grade 3, IC and IIA endometrial carcinoma.
    Foad I; Sharawy I; Mostafa E; Margergis M; Hussein T
    J Egypt Natl Canc Inst; 2007 Jun; 19(2):163-9. PubMed ID: 19034346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation.
    Kelly MG; O'Malley D; Hui P; McAlpine J; Dziura J; Rutherford TJ; Azodi M; Chambers SK; Schwartz PE
    Gynecol Oncol; 2004 Dec; 95(3):469-73. PubMed ID: 15581948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of adjuvant pelvic radiation "sandwiched" between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma.
    Einstein MH; Frimer M; Kuo DY; Reimers LL; Mehta K; Mutyala S; Huang GS; Hou JY; Goldberg GL
    Gynecol Oncol; 2012 Jan; 124(1):21-5. PubMed ID: 22035806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.
    Murphy KT; Rotmensch J; Yamada SD; Mundt AJ
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1272-6. PubMed ID: 12654437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus.
    Hong JC; Foote J; Broadwater G; Gaillard S; Havrilesky LJ; Chino JP
    Int J Gynecol Cancer; 2017 May; 27(4):720-729. PubMed ID: 28375927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer.
    Milgrom SA; Kollmeier MA; Abu-Rustum NR; Tew WP; Sonoda Y; Barakat RR; Alektiar KM
    Gynecol Oncol; 2013 Sep; 130(3):436-40. PubMed ID: 23800696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.
    Young MR; Higgins SA; Ratner E; Yu JB; Mani S; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Damast S
    Int J Gynecol Cancer; 2015 Mar; 25(3):431-9. PubMed ID: 25621409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early stage papillary serous or clear cell carcinoma confined to or involving an endometrial polyp: outcomes with and without adjuvant therapy.
    Chang-Halpenny CN; Natarajan S; Hwang-Graziano J
    Gynecol Oncol; 2013 Dec; 131(3):598-603. PubMed ID: 24135679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology).
    Mustea A; Koensgen D; Belau A; Sehouli J; Lichtenegger W; Schneidewind L; Sommer H; Markmann S; Scharf JP; Ehmke M; Ledwon P; Braicu I; Zygmunt M; Koehler G
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):975-83. PubMed ID: 23995698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenocarcinoma of the endometrium treated with combined irradiation and surgery: study of 437 patients.
    Touboul E; Belkacémi Y; Buffat L; Deniaud-Alexandre E; Lefranc JP; Lhuillier P; Uzan S; Jannet D; Uzan M; Antoine M; Huart J; Ganansia V; Milliez J; Blondon J; Housset M; Schlienger M
    Int J Radiat Oncol Biol Phys; 2001 May; 50(1):81-97. PubMed ID: 11316550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival outcomes of adjuvant radiotherapy and chemotherapy in women with stage I serous papillary and clear cell carcinoma of the endometrium: a Korean multicenter study.
    Kim M; Kwon BS; Chang HK; Lee S; Chang SJ; Choi JY; Park SY; Lee M; Ryu HS; Kim YB
    J Gynecol Oncol; 2019 May; 30(3):e44. PubMed ID: 30887761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multi-institutional analysis of sequential versus 'sandwich' adjuvant chemotherapy and radiotherapy for stage IIIC endometrial carcinoma.
    Onal C; Sari SY; Yildirim BA; Yavas G; Gultekin M; Guler OC; Akyurek S; Yildiz F
    J Gynecol Oncol; 2019 May; 30(3):e28. PubMed ID: 30887753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases.
    Black C; Feng A; Bittinger S; Quinn M; Neesham D; McNally O
    Int J Gynecol Cancer; 2016 Jan; 26(1):133-40. PubMed ID: 26588230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel model to predict cancer-specific survival in patients with early-stage uterine papillary serous carcinoma (UPSC).
    Chen L; Liu X; Li M; Wang S; Zhou H; Liu L; Cheng X
    Cancer Med; 2020 Feb; 9(3):988-998. PubMed ID: 31846222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of adjuvant therapy in women with uterine papillary serous cancer.
    Al Husaini H; Soudy H; Darwish A; Ahmed M; Eltigani A; Edesa W; Abdelsalam M
    Ann Saudi Med; 2012; 32(1):27-31. PubMed ID: 22156636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extrauterine Spread, Adjuvant Treatment, and Prognosis in Noninvasive Uterine Papillary Serous Carcinoma of the Endometrium: A Retrospective Multicenter Study.
    Boyraz G; Salman MC; Basaran D; Ozgul N; Turan T; Turkmen O; Kimyon GC; Ozkan NT; Cagan M; Gungor T; Meydanli MM; Gungorduk K; Gulseren V; Sanci M; Yuce K
    Int J Gynecol Cancer; 2017 Jan; 27(1):102-108. PubMed ID: 27668395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.